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The endeavor to sequence the whole human genome lead not only to the knowledge 
acquisition regarding the human genetic information but as well to the development of new 
sequencing methods and technologies. In order to keep up with progress in genetic field in 
many clinical and research laboratories the new massive parallel sequencing equipment is 
being utilized. On the market are currently established four leading platforms – Illumina, 
Solid, Ion Torrent and 454 Life Technologies. The process of sequencing analysis can be 
summarized into three main steps – the sequencing library preparation, sequencing itself, 
variant calling and data analysis.  Each part of the sequencing analysis exhibits certain 
specifics, we need to count with and as well its pitfalls, we need to avoid or to minimalize 
their impact on the analysis final result. Recently new methods termed sequencing of the 3rd 
generation are being developed, enabling sequence of a single DNA molecule to be 
determined without previous amplification. NGS technologies provide those days laboratories 
with ability to choose their own preferences in sequencing, where the laboratory can choose 
whether it needs data obtained by whole genome sequencing, exome sequencing or whether to 
test certain group of genes in so called panel. 
In the practical part of this study is described the establishment of next generation 
sequencing in the diagnostic laboratory and optimalization of required processes. The trial 
group of 191 patients with diagnosis of hereditary cardiomyopathy was selected in 
collaboration with cardiology clinic of IKEM and University Hospital Motol in order to detect 
germinal mutations. In 65 patients the TruSight Cardiomyopathy panel was utilized, and 
causal mutation was uncovered in 48 patients. In remaining 126 samples comprising 42 
families the clinical exome was sequenced using TruSight One kit and revealing causal 
mutation in 27 more families. The usage of NGS methods was tested as well in group of 8 
patients from 3 families with serious genetic condition, where expanded exome probes 
covering 37 Mb were employed. 
